2019
May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension
Beaney T, Burrell L, Castillo R, Charchar F, Cro S, Damasceno A, Kruger R, Nilsson P, Prabhakaran D, Ramirez A, Schlaich M, Schutte A, Tomaszewski M, Touyz R, Wang J, Weber M, Poulter N, Burazeri G, Qirjako G, Roshi E, Cunashi R, Fernandes M, Pereira S, Neto M, Oliveira P, Feijão A, Cerniello Y, Marin M, Vasquez F, Espeche W, Stisman D, Fuentes I, Zilberman J, Rodriguez P, Babinyan K, Engibaryan A, Avagyan A, Minasyan A, Gevorkyan A, Carnagarin R, Carrington M, Sharman J, Lee R, Perl S, Niederl E, Malik F, Choudhury S, Al Mamun M, Ishraquzzaman M, Anthony F, Connell K, De Backer T, Krzesinski J, Houenassi M, Houehanou C, Sokolovic S, Bahtijarevic R, Tiro M, Mosepele M, Masupe T, Barroso W, Gomes M, Feitosa A, Brandão A, Miranda R, Azevedo V, Dias L, Garcia G, Martins I, Dzudie A, Kingue S, Djomou F, Njume E, Khan N, Lanas F, Garcia M, Paccot M, Torres P, Li Y, Liu M, Xu L, Li L, Chen X, Deng J, Zhao W, Fu L, Zhou Y, Lopez-Jaramillo P, Otero J, Camacho P, Accini J, Sanchez G, Arcos E, M’Buyamba-Kabangu J, Katamba F, Ngoyi G, Buila N, Bayauli P, Mbolla B, Bakekolo P, Landa C, Kaky G, Kramoh E, Ngoran Y, Olsen M, Valoy L, Santillan M, Rafael G, Peñaherrera C, Villalba J, Ramirez M, Arteaga F, Delgado P, Beistline H, Cappuccio F, Keitley J, Tay T, Goshu D, Kassie D, Gebru S, Pathak A, Denolle T, Tsinamdzgvrishvili B, Trapaidze D, Sturua L, Abesadze T, Grdzelidze N, Grabfelder M, Krämer B, Schmeider R, Twumasi-Ankrah B, Tannor E, Lincoln M, Deku E, Quintana F, Kenerson J, Baptiste E, Saintilmond W, Barrientos A, Peiger B, Lagos A, Forgas M, Lee V, Tomlinson B, Járai Z, Páll D, More A, Maheshwari A, Verma N, Sharma M, Mukherjee T, Patil M, Jose A, More A, Takalkar A, Turana Y, Widyantoro B, Danny S, Djono S, Handari S, Tambunan M, Tiksnadi B, Hermiawaty E, Tavassoli E, Zolfaghari M, Dolan E, O'Brien E, Borghi C, Ferri C, Torlasco C, Parati G, Nwokocha C, Nwokocha M, Ogola E, Gitura B, Barasa A, Barasa F, Wairagu A, Nalwa W, Najem R, Abu Alfa A, Fageh H, Msalam O, Derbi H, Bettamar K, Zakauskiene U, Vickiene A, Calmes J, Alkerwi A, Gantenbein M, Ndhlovu H, Masiye J, Chirwa M, Nyirenda N, Dhlamini T, Chia Y, Ching S, Devaraj N, Ouane N, Fane T, Kowlessur S, Ori B, Heecharan J, Alcocer L, Chavez A, Ruiz G, Espinosa C, Gomez-Alvarez E, Neupane D, Bhattarai H, Ranabhat K, Adhikari T, Koirala S, Toure I, Soumana K, Wahab K, Omotoso A, Sani M, Okubadejo N, Nadar S, Al-Riyami H, Ishaq M, Memon F, Sidique S, Choudhry H, Khan R, Ayala M, Maidana A, Bogado G, Ona D, Atilano A, Granada C, Bartolome R, Manese L, Mina A, Dumlao M, Villaruel M, Gomez L, Jóźwiak J, Małyszko J, Banach M, Mastej M, de Carvalho Rodrigues M, Martins L, Paval A, Dorobantu M, Konradi A, Chazova I, Rotar O, Spoares M, Viegas D, Almustafa B, Alshurafa S, Brady A, Bovet P, Viswanathan B, Oladapo O, Russell J, Brguljan-Hitij J, Bozic N, Knez J, Dolenc P, Hassan M, Woodiwiss A, Myburgh C, Vally M, Ruilope L, Molinero A, Rodilla E, Gijón-Conde T, Beheiry H, Ali I, Osman A, fahal N, Osman H, Altahir F, Persson M, Wuerzner G, Burkard T, Wang T, Lin H, Pan H, Chen W, Lin E, Mondo C, Ingabire P, Khomazyuk T, Krotova V, Negresku E, Evstigneeva O, Bazargani N, Agrawal A, Bin Belaila B, Suhail A, Muhammed K, Shuri H, Wainford R, Levy P, Boggia J, Garré L, Hernandez-Hernandez R, Octavio-Seijas J, Lopez-Rivera J, Morr I, Duin A, Huynh M, Cao S, Nguyen V, To M, Phan H, Cockroft J, McDonnell B, Goma F, Syatalimi C, Chifamba J, Gwini R, Tiburcio O, Xia X. May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. European Heart Journal 2019, 40: 2006-2017. PMID: 31041440, PMCID: PMC6600128, DOI: 10.1093/eurheartj/ehz300.Peer-Reviewed Original ResearchConceptsMay Measurement MonthBlood pressureAntihypertensive medicationsMeasurement MonthDiastolic blood pressureSystolic blood pressureHigh blood pressureSystematic screening programmeMore participantsMMM 2018Untreated hypertensionBP readingsFormal screeningBP measurementsDisease burdenMultiple imputationHypertensionScreening programMedicationsMmHgInternational SocietyMonthsScreening campaignParticipantsIndividuals
2013
Acute Kidney Injury and Bisphosphonate Use in Cancer: A Report From the Research on Adverse Drug Events and Reports (RADAR) Project
Edwards BJ, Usmani S, Raisch DW, McKoy JM, Samaras AT, Belknap SM, Trifilio SM, Hahr A, Bunta AD, Abu-Alfa A, Langman CB, Rosen ST, West DP. Acute Kidney Injury and Bisphosphonate Use in Cancer: A Report From the Research on Adverse Drug Events and Reports (RADAR) Project. JCO Oncology Practice 2013, 9: 101-106. PMID: 23814519, PMCID: PMC3595436, DOI: 10.1200/jop.2011.000486.Peer-Reviewed Original ResearchConceptsAcute kidney injuryZoledronic acidKidney injuryAdverse eventsProportional reporting ratioFDA AERSBisphosphonate useSafety signalsReporting ratioAdverse drug eventsDrug Administration adverse eventsAdverse drug reactionsCancer clinical trialsPremorbid diseaseRenal injuryRenal problemsMean ageMultiple myelomaDrug eventsDrug reactionsClinical trialsProstate cancerBreast cancerCancer settingUS Food
2010
Experience with outpatient computed tomographic-guided renal biopsy.
Margaryan A, Perazella MA, Mahnensmith RL, Abu-Alfa AK. Experience with outpatient computed tomographic-guided renal biopsy. Clinical Nephrology 2010, 74: 440-5. PMID: 21084047, DOI: 10.5414/cnp74440.Peer-Reviewed Original ResearchConceptsNative kidney biopsiesKidney biopsyRenal biopsyPost-biopsy observation periodInpatient observation periodObservation periodLow complication rateTime of admissionYale-New Haven Medical CenterDuration of procedureInstances of deathHemoglobin concentration changesDetectable bleedingSerum creatinineComplication rateMean ageRenal sizeAdequate tissueMedical CenterOutpatient unitDiagnostic tissueBiopsyLaboratory dataTransfusionPatientsRenal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature
Cuffy MC, Singh M, Formica R, Simmons E, Abu Alfa AK, Carlson K, Girardi M, Cowper SE, Kulkarni S. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrology Dialysis Transplantation 2010, 26: 1099-1101. PMID: 21079195, DOI: 10.1093/ndt/gfq693.Peer-Reviewed Case Reports and Technical NotesConceptsNephrogenic systemic fibrosisRenal transplantationSystemic fibrosisSymptoms of NSFEarly renal transplantationUnderwent renal transplantationRare fibrosing disorderStandard therapy existsRenal functionFibrosing disorderRenal diseaseCase reportTherapy existsPatient's lesionTherapeutic modalitiesTransplantationPatientsLesionsFibrosisPhotopheresisPlasmapheresisImatinibSymptomsCareful considerationDisease
2009
Gadolinium‐containing magnetic resonance image contrast agent promotes fibrocyte differentiation
Vakil V, Sung JJ, Piecychna M, Crawford JR, Kuo P, Abu‐Alfa A, Cowper SE, Bucala R, Gomer RH. Gadolinium‐containing magnetic resonance image contrast agent promotes fibrocyte differentiation. Journal Of Magnetic Resonance Imaging 2009, 30: 1284-1288. PMID: 19937928, PMCID: PMC2787835, DOI: 10.1002/jmri.21800.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsNephrogenic systemic fibrosisSerum amyloid PFibrocyte differentiationDifferentiation of monocytesNSF patientsBlood mononuclear cellsHemodialysis patientsInterleukin-12Mononuclear cellsPurified monocytesFibroblast-like cellsFibrotic lesionsHealthy controlsSystemic fibrosisAmyloid PContrast agentsPatientsMonocytesDifferentiation inhibitorWiley-LissFibrocytesOmniscanDifferentiation protocolsCellsSuccessful Use of Intraperitoneal Daptomycin in the Treatment of Vancomycin-Resistant Enterococcus Peritonitis
Huen SC, Hall I, Topal J, Mahnensmith RL, Brewster UC, Abu-Alfa AK. Successful Use of Intraperitoneal Daptomycin in the Treatment of Vancomycin-Resistant Enterococcus Peritonitis. American Journal Of Kidney Diseases 2009, 54: 538-541. PMID: 19237231, DOI: 10.1053/j.ajkd.2008.12.017.Peer-Reviewed Case Reports and Technical NotesConceptsIntraperitoneal daptomycinPeritoneal dialysis-associated peritonitisDialysis-associated peritonitisEnterococcus faecium peritonitisSuch resistant organismsPeritoneal dialysis therapyTreatment of patientsVancomycin-resistant enterococciDialysis therapyDialysate exchangePeritonitisResistant organismsPatientsDaptomycinDextrose solutionAdditional studiesTreatmentSuccessful useRelapseDosingTherapyPharmacokineticsInfection
2008
The Association of Hashimoto Disease and Congo Red Negative Amyloidosis
Chaiban JT, Kalache SM, Salti I, Abu Alfa A, Shabb N. The Association of Hashimoto Disease and Congo Red Negative Amyloidosis. The American Journal Of The Medical Sciences 2008, 336: 293-296. PMID: 18794630, DOI: 10.1097/maj.0b013e31815b9d51.Peer-Reviewed Original ResearchConceptsCongo red stainHashimoto's thyroiditisPrimary amyloidosisMultiple organ involvementRed stainMonoclonal immunoglobulin light chainsOrgan involvementRenal failureHeart failureHashimoto's diseaseAmyloid depositionEnlarged tongueRare caseImmunoglobulin light chainsSystemic amyloidosisExtracellular depositionImmunofixation studiesAmyloidosisUltrastructural featuresThyroiditisPatientsLight chainStainEarly stagesBiopsy
2007
Are Patients with Moderate Renal Failure at Risk for Developing Nephrogenic Systemic Fibrosis?
Saab G, Abu-Alfa A. Are Patients with Moderate Renal Failure at Risk for Developing Nephrogenic Systemic Fibrosis? Radiology 2007, 244: 930-932. PMID: 17709844, DOI: 10.1148/radiol.2443070351.Peer-Reviewed Original ResearchWill dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?
Saab G, Abu-Alfa A. Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration? American Journal Of Roentgenology 2007, 189: w169. PMID: 17715089, DOI: 10.2214/ajr.07.2252.Peer-Reviewed Original Research
2006
Long‐term comparison of sevelamer hydrochloride to calcium‐containing phosphate binders
BREWSTER UC, CIAMPI MA, ABU‐ALFA A, REILLY RF. Long‐term comparison of sevelamer hydrochloride to calcium‐containing phosphate binders. Nephrology 2006, 11: 142-146. PMID: 16669977, DOI: 10.1111/j.1440-1797.2006.00544.x.Peer-Reviewed Original ResearchConceptsCalcium-containing bindersSerum phosphorus concentrationLower serum bicarbonate concentrationEnd-stage renal diseaseCalcium-phosphorus productSerum bicarbonate concentrationSevelamer hydrochloridePhosphate bindersCalcium-containing phosphate bindersElevated calcium-phosphorus productHigher serum phosphorus concentrationsMmol2/L2Retrospective chart reviewLong-term efficacyCa-P productLong-term comparative studiesBicarbonate concentrationESRD patientsChart reviewRenal diseaseCalcium loadPatientsLong-term comparisonTarget goalsEfficacy
2004
Superiority of Icodextrin Compared with 4.25% Dextrose for Peritoneal Ultrafiltration
Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T, Nash K, Sorkin M, Mujais S, Group O. Superiority of Icodextrin Compared with 4.25% Dextrose for Peritoneal Ultrafiltration. Journal Of The American Society Of Nephrology 2004, 16: 546-554. PMID: 15625070, DOI: 10.1681/asn.2004090793.Peer-Reviewed Original ResearchConceptsIcodextrin groupNegative net ultrafiltrationNet ultrafiltrationPeritoneal ultrafiltrationWeek 2Week 1Control groupDouble-blind trialPercentage of patientsAutomated Peritoneal DialysisPeritoneal dialysisTreatment groupsControlled EvaluationHigh transportersClinical observationsIcodextrinStudy periodBaselineLong dwellPatientsDextroseSolute removalGroupEfficiency ratioMulticenterCinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG. Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. New England Journal Of Medicine 2004, 350: 1516-1525. PMID: 15071126, DOI: 10.1056/nejmoa031633.Peer-Reviewed Original ResearchConceptsParathyroid hormone levelsPrimary end pointSecondary hyperparathyroidismHormone levelsPlacebo groupCinacalcet groupLow parathyroid hormone levelsSerum calcium-phosphorus productIntact parathyroid hormone levelsEnd pointCalcium-phosphorus productEfficacy assessment phaseParathyroid hormone valuesPatients Receiving HemodialysisPlacebo-controlled trialPercentage of patientsAdverse clinical outcomesCalcium-phosphorus homeostasisCalcium-sensing receptorClinical outcomesVitamin DDaily dosesStandard treatmentHormone valuesCardiovascular disease
2003
Addition of sertraline to other therapies to reduce dialysis‐associated hypotension
BREWSTER UC, CIAMPI MA, ABU‐ALFA A, PERAZELLA MA. Addition of sertraline to other therapies to reduce dialysis‐associated hypotension. Nephrology 2003, 8: 296-301. PMID: 15012700, DOI: 10.1111/j.1440-1797.2003.00216.x.Peer-Reviewed Original ResearchConceptsDialysis-associated hypotensionCentral blood volumePeripheral vascular resistanceBlood pressureCardiac outputBlood volumeEnd-stage renal disease patientsInitiation of dialysisRenal disease patientsDiastolic blood pressureSystolic blood pressureEffects of sertralineTermination of dialysisAddition of sertralineUltrasound dilution techniqueVascular resistanceArterial pressureHaemodynamic measurementsDisease patientsPatientsControl phaseSertralineTherapyDialysisHypotensionVascular Access Surveillance: Evaluation of Combining Dynamic Venous Pressure and Vascular Access Blood Flow Measurements
Hoeben H, Abu-Alfa AK, Reilly RF, Aruny JE, Bouman K, Perazella MA. Vascular Access Surveillance: Evaluation of Combining Dynamic Venous Pressure and Vascular Access Blood Flow Measurements. American Journal Of Nephrology 2003, 23: 403-408. PMID: 14566106, DOI: 10.1159/000074297.Peer-Reviewed Original ResearchConceptsArteriovenous fistulaArteriovenous graftsThrombosis rateThrombotic eventsVascular accessAccess blood flow measurementsSurveillance protocolBlood flow measurementsHemodialysis patientsVenous pressureDynamic venous pressureVascular access thrombosisChronic hemodialysis patientsAccess thrombosisEarly repairIntervention ratesBACKGROUND/Cutoff levelMorbid problemPatientsLow specificityAccess yearCombined monitoringStenosisThrombosis
2002
Observations on HIV-Associated Renal Disease in the Era of Highly Active Antiretroviral Therapy
Cosgrove CJ, Abu-Alfa AK, Perazella MA. Observations on HIV-Associated Renal Disease in the Era of Highly Active Antiretroviral Therapy. The American Journal Of The Medical Sciences 2002, 323: 102-106. PMID: 11863077, DOI: 10.1097/00000441-200202000-00009.Peer-Reviewed Original ResearchConceptsHIV-associated nephropathyActive antiretroviral therapySerum creatinineRenal functionRenal diseaseRenal outcomesAntiretroviral therapyViral loadRenal lesionsHighly Active Antiretroviral TherapyAngiotensin-converting enzyme inhibitorEffect of HAARTNon-HAART groupAdvanced renal failureInitiation of dialysisRenal function parametersStable renal functionVariety of lesionsHAART groupCD4 countHAART eraRenal evaluationRenal insufficiencyRenal ultrasoundBaseline characteristicsHemodynamics in patients with intradialytic hypotension treated with cool dialysate or midodrine
Hoeben H, Abu-Alfa AK, Mahnensmith R, Perazella MA. Hemodynamics in patients with intradialytic hypotension treated with cool dialysate or midodrine. American Journal Of Kidney Diseases 2002, 39: 102-107. PMID: 11774108, DOI: 10.1053/ajkd.2002.29887.Peer-Reviewed Original ResearchConceptsPeripheral vascular resistanceCentral blood volumeDialysis-associated hypotensionCardiac outputIntradialytic hypotensionIntradialytic hemodynamicsCool dialysateEnd-stage renal disease populationTermination of hemodialysisInitiation of hemodialysisMean arterial pressureRenal disease populationUltrasound dilution techniqueVascular resistanceHemodynamic stabilityArterial pressureBlood pressureUltrafiltration volumeDisease populationHypotensionBlood volumePatientsMidodrineHemodialysisHemodynamics
2001
Treatment of Severe Intradialytic Hypotension With the Addition of High Dialysate Calcium Concentration to Midodrine and/or Cool Dialysate
Alappan R, Cruz D, Abu-Alfa A, Mahnensmith R, Perazella M. Treatment of Severe Intradialytic Hypotension With the Addition of High Dialysate Calcium Concentration to Midodrine and/or Cool Dialysate. American Journal Of Kidney Diseases 2001, 37: 294-299. PMID: 11157369, DOI: 10.1053/ajkd.2001.21292.Peer-Reviewed Original ResearchConceptsHigh dialysate calcium concentrationSevere intradialytic hypotensionDialysate calcium concentrationIntradialytic hypotensionBlood pressureEnd-stage renal disease populationCalcium concentrationLow dialysate calciumSeverity of hypotensionMean arterial pressurePeripheral vascular resistanceIntradialytic blood pressureRenal disease populationProspective crossover studyTreatment of patientsMultiple pathogenic factorsType of therapyDialysate calciumHemodynamic instabilityVascular resistanceHemodynamic stabilityArterial pressureCrossover studyCardiac outputCool dialysate
2000
Ace inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients
Abu-Alfa A, Cruz D, Perazella M, Mahnensmith R, Simon D, Bia M. Ace inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients. American Journal Of Kidney Diseases 2000, 35: 1076-1082. PMID: 10845820, DOI: 10.1016/s0272-6386(00)70043-6.Peer-Reviewed Original ResearchMeSH KeywordsAnemiaAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureBlood TransfusionCross-Over StudiesDiabetes ComplicationsDrug ResistanceEpoetin AlfaErythropoietinFemaleFollow-Up StudiesHematinicsHematocritHospitalizationHumansInfectionsKidney Failure, ChronicLisinoprilMaleMiddle AgedProspective StudiesRecombinant ProteinsRenal DialysisTime FactorsConceptsACE inhibitor therapyACE inhibitorsHemodialysis patientsRHuEPO resistanceInhibitor therapyRecombinant human erythropoietin resistanceRecombinant human erythropoietin (rHuEPO) requirementsBlood pressure controlChronic renal failureDuration of infectionRHuEPO doseTransfusion requirementsErythropoietin resistanceRenal failureDialysis patientsHospitalization daysLaboratory parametersRHuEPO dosesAntihypertensive agentsCrossover studyErythropoietin requirementsInclusion criteriaPatientsAverage ageEnzyme inhibitors
1998
Reduction in arteriovenous graft impairment: Results of a vascular access surveillance protocol
Cayco A, Abu-Alfa A, Mahnensmith R, Perazella M. Reduction in arteriovenous graft impairment: Results of a vascular access surveillance protocol. American Journal Of Kidney Diseases 1998, 32: 302-308. PMID: 9708617, DOI: 10.1053/ajkd.1998.v32.pm9708617.Peer-Reviewed Original ResearchConceptsDynamic venous pressureHistorical control groupVenous pressureArteriovenous graftsSurveillance protocolStudy groupBlood flow rateThrombosis rateControl groupSimilar historical control groupHemodialysis vascular accessSynthetic arteriovenous graftsLower thrombosis rateML/minGraft impairmentVenous stenosisHD sessionVascular accessVascular stenosisPatientsScreening testStenosisStudy periodFrustrating problemConsecutive readings
1996
Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: Any evidence of erythropoietin resistance?
Cruz D, Perazella M, Abu-Alfa A, Mahnensmith R. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: Any evidence of erythropoietin resistance? American Journal Of Kidney Diseases 1996, 28: 535-540. PMID: 8840943, DOI: 10.1016/s0272-6386(96)90464-3.Peer-Reviewed Original ResearchConceptsChronic hemodialysis patientsEnzyme inhibitor therapyACE inhibitorsHemodialysis patientsInhibitor therapySevere anemiaGroup 2Group 1End-stage renal diseaseExacerbation of anemiaSuppression of angiotensinChronic renal failureCongestive heart failureTherapy of anemiaBone marrow responseSignificant differencesRed blood cell productionRecombinant human EpoRHuEPO responseChronic hemodialysisErythropoietin resistanceRenal transplantationBaseline characteristicsHospital daysRenal failure